MACSF

COMMUNIQUÉS West-GlobeNewswire

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
09/07/2025
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of [...]
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
09/07/2025
PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy IND clearance follows the granting of European Medicine Agency (EMA) orphan drug [...]
Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025
09/07/2025
NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
09/07/2025
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, [...]
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
09/07/2025
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Nusano Achieves Key Technology Milestone Enabling Simultaneous Production of Multiple Radioisotopes
09/07/2025
Pairing of custom-built klystrons and fast-pulse modulators enable production of up to 12 radioisotopes in a single run Power and efficiency of Nusano system to surpass existing commercial methodologies Beam time [...]
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
09/07/2025
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass [...]
Aurora Spine Announces Initial Surgeries using its AERO™ Lumbar Fusion System
09/07/2025
CARLSBAD, CALIFORNIA, July 09, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, [...]
Glucose Health, Inc. Formulations Have Always Been Free of Artificial Colors & Synthetic Dyes—Our Competitors Are Only Playing Catch-Up
09/07/2025
BENTONVILLE, Ark., July 09, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), the leading innovator in soluble fiber powdered drink mixes for metabolic wellness, proudly affirms that its flagship brands, [...]
Communiqué de presse : Sanofi fait galoper Zeus, le cheval mécanique de la cérémonie d’ouverture des Jeux Olympiques, au Mont-Saint-Michel
09/07/2025
Sanofi fait galoper Zeus, le cheval mécanique de la cérémonie d’ouverture des Jeux Olympiques, au Mont-Saint-Michel Zeus a été vu par un demi-million de personnes depuis le début de la tournée . Photos et vidéos de l’ [...]
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
09/07/2025
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
09/07/2025
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), [...]
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
09/07/2025
REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), [...]
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
09/07/2025
[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a study No treatment limited toxicities observed Patient remains on study with stable disease [...]
Theratechnologies présente ses résultats financiers pour le deuxième trimestre de 2025
09/07/2025
Les revenus totaux s’élèvent à 17,7 millions de dollars pour le deuxième trimestre de 2025 et à 36,8 millions de dollars pour le premier semestre de l’exercice 2025 Un BAIIA ajusté 1 positif a été dégagé pour un [...]
Theratechnologies Reports Financial Results for the Second Quarter 2025
09/07/2025
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025 Positive Adjusted EBITDA 1 for the fifth straight quarter Subsequent to quarter end, Theratechnologies entered into a [...]
Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
09/07/2025
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and [...]
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
09/07/2025
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without Tolerance SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage [...]
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
09/07/2025
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- [...]

Pages